Editorial   **open access**

Epigenetics – The New Kid on the Block

Lundstrom K*

Pan Therapeutics, Lutry, Switzerland

*Corresponding author: Lundstrom K, Pan Therapeutics, Lutry, Switzerland, Tel: 41 79 776 63 51; E-mail: lundstromkenneth@gmail.com

Editorial

The foundation of the laws of inheritance was established by the Austrian monk Gregor Mendel in the nineteenth century when he conducted hybridization experiments in *Pisum sativum* (garden peas). The real boost in genetics was obviously the discovery of the DNA structure by Watson and Crick [1]. The more recent progress in bioinformatics, genomics and proteomics has established a strong link between genetic preposition and disease [2]. A number of mutations have been linked to development of disease [3,4]. Particularly, cancer has been associated with mutations leading to uncontrolled gene expression of oncogenes or tumor suppressor genes [5]. However, the common consensus in the scientific community has been the proposal of two-event models for carcinogenesis, where mutations are associated with cell division and the target tissue is allowed to grow in size [6]. The relatively recent discovery of epigenetics affecting gene expression has shed new light on understanding the origin of human disease and its treatment and prevention [7].

Epigenetics has been defined as mechanisms outside the scope of conventional genetics as epigenetic mechanisms do not involve any modifications to the primary DNA sequence [8]. Moreover, the reversible nature of epigenetics has made therapeutic applications attractive. The three major epigenetic mechanisms comprise of DNA methylations, histone modifications and RNA interference (RNAi) [9]. In this context, DNA methyltransferase (DNMT) inhibitors have been targeted against schizophrenia, bipolar disorders and various cancers. For instance, azacytidine and decitabine have been shown to be efficient epigenetic modulators although toxicity and chemical stability issues have restricted their use in cancer therapy [10]. Histone deacetylase (HDAC) inhibitors have been approved for the treatment of cardiac hypertrophy and heart failure [11], Parkinson's disease [12] and cancer [11]. Furthermore, HDAC inhibitors combined with DNA methylating agents have been subjected to studies in a schizophrenia mouse model [12]. Moreover, HDAC inhibitors have been combined with the DNMT inhibitor azacytidine for the treatment of esophageal squamous cell carcinoma (ESCC) and esophageal adenomacarcinoma (EAC) cells [13]. Also, the combination of DNMT and HDAC inhibitors was used for the treatment of cutaneous T-cell lymphoma [14]. RNAi and particularly micro RNAs (miRNAs) have been demonstrated to interfere with the regulation of gene expression and thereby present attractive targets for drug development. For example, correlation between tumor stage and poor clinical outcome has been associated with miR-135b up-regulation in human colorectal cancer [15]. Similarly, differential expression of miR-21, miR-126 and miR-143 has been linked to cervical cancer and therapeutic interventions have included inhibition of miR-21 activity and supplementation of miR-143 [16]. The attraction of miRNA-based therapy is the identification of more than 1800 miRNAs currently deposited in databases [17], of which a large number have been directly or indirectly linked to human disease [9,18].

What is next for epigenetics in understanding the association to prevention of disease and therapeutic intervention? In addition to classic approaches of compound screening for DNMT and HDAC inhibitors and development of improved stability and delivery of miRNAs, the following issues also play an important role for the impact of epigenetics. Firstly, dietary intake and lifestyle adjustments have been demonstrated to provide a strong influence on the epigenome. For instance, several cruciferous vegetables, green tea and spices have resulted in epigenetic modifications in female cancers [19]. Although some meta-analysis has not provided conclusive results, one study showed that increased consumption of total dairy food, excluding milk, might reduce the risk of breast cancer [20]. Likewise, soy isoflavone intake decreased the breast cancer risk significantly based on a meta-analysis of 4 studies on breast cancer occurrence and 14 studies on breast cancer incidence [21].

Cruciferous vegetables such as kale, cabbage, Brussels sprouts and broccoli contain sulforaphane (SFN) and indol-3-carbinol (I3C), which can act as DNMT and HDAC inhibitors and are also involved in miRNA regulation [22]. Extra virgin olive oil has also showed a positive impact on reduction of cancer risk [23]. For instance, a 4-fold stimulation of type I cannabinoid receptor (CB1) expression was observed in the colon of rats receiving 10 days of dietary extra virgin olive oil supplementation. Simultaneously, both miR-23a and miR301a known to be associated to the pathogenesis of colorectal cancer showed a 50% decrease. In relation to prostate cancer, it has been demonstrated that the phytoestrogen genistein demethylates CpG islands in promoter regions leading to enhanced protein expression [24]. Genistein can also enhance the expression of several tumor suppressor genes in prostate cancer cell lines, which has been attributed to demethylation and acetylation events [25] or increased expression of histone acetyltransferases [26]. The polyphenol resveratrol has showed anti-cancer activity both in vitro and in vivo, which could result in applications for both chemoprevention and prostate cancer therapy [27]. Recently, resveratrol analogs with chemical modifications have been designed to improve the low oral bioavailability and rapid metabolism to provide improved pharmacokinetic parameters and superiority in clinical applications [28]. Furthermore, consummation of vegetables and fruits showed a statistically significant inverse association with the risk of stomach cancer [29]. Also, green tea containing high concentrations of anti-oxidants has demonstrated prevention of esophageal and colon cancer [30].

One interesting but often neglected aspect that plays an important role on epigenetic functions is the composition of the gut microbiome and how it is influenced by dietary intake. Dietary factors and environmental toxins strongly affect the metabolites, which serve as cofactors and allosteric regulators of epigenetic functions and are produced by the gut microbiota [31]. Furthermore, the epigenome of the offspring is influenced by maternal and neonatal nutrition due to

the interaction of consumed food and the composition of the gut microbiota [32]. The link between the epigenetic profile and bacterial predominance was demonstrated in pregnant women, where Firmicutes and Bacteroidetes were the dominant gut microbe groups in obese individuals with differential methylation of gene promoters [33]. It has also been described that the gut microbes are responsible for the conversion of dietary fibers into short-chain fatty acids associated with histone hyperacetylation [34]. Gut bacteria also modulate N-nitroso compounds and heterocyclic aromatic amines derived from fat and red meat and considered as factors elevating the risk of colorectal cancer [35].

Finally, individual genetic and epigenetic differences need to be addressed for therapeutic interventions also for nutritional requirements. For example, in a case-report study a breast cancer patient was not eligible to chemotherapy due to some severe symptoms [36]. Nutritional deficiencies were detected through specialized testing for metabolic, gastrointestinal and immunological functions and after correction allowed to provide treatment to the patients. Nutrigenomics has also played an important role in preparing diets for individual genotypes [37]. In this context, Korean red ginseng has been recommended for the prevention of *Helicobacter pylori*-associated gastric cancer [38].

In conclusion, epigenetic mechanisms have been demonstrated to play an important role in disease development. The reversible nature of epigenetic functions has made targeting the epigenome attractive. A number of DNMT and HDAC inhibitors have been approved as medicines, either individually or for combination therapy. The rapid and important discovery of the many miRNAs affecting gene expression regulation and their association with human disease has further highlighted the importance of epigenetics in future medicine. The link between epigenetics, diet and disease will further strengthen the potential of developing better treatment for disease, but also most importantly pay serious attention to prevention, which will serve well from social, ethical and economic aspects.

References

1. Watson JD, Crick FHC (1953) A structure for deoxyribose nucleic acid. Nature 171: 737-738.

2. Scitable. Genes and Diseases. Accessed on 11Apr 2016.

3. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, et al. (2002) The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122: 867-874.

4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.

5. Pierotti MA, Sozzi G, Croce CM (2003) Mechanisms of oncogene activation. [6thedn], In: Holland-Frei Cancer Medicine, Kufe DW, Pollock RE, Weichselbaum RR (eds.) BC Decker, New York.

6. Moolgavkar SH, Venzon DJ (1979) Two-event models for carcinogenesis: incidence curves for childhood and adult tumors. Mathematical Biosci 47: 55-77.

7. Feisenfeld G (2014) A brief history of epigenetics. Cold Spring Harb Prespect Biol 6: a018200.

8. Su LJ, Mahabir S, Ellison GL, McGuinn LA, Reid BC (2012) Epigenetic contributions to the relationsip between cancer and dietary intake of nutrients, bioactive food components and environmental toxicants. Front Genetics 2:91.

9. Lundstrom K (2011) Micro RNA in disease and gene therapy. Curr Drug Discov Technol 8: 76-86.

10. Gnyszka A, Jastrzebski Z, Flis S (2013) DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of anticancer. Anticancer Res 33: 2989-2996.

11. Yoon S, Eom GH (2016) HDAC and HDAC inhibitor: from cancer to cardiovascular disease. Chonnam Med J 52: 1-11.

12. Harrison IF, Dexter DT (2013) Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol Ther 140: 34-52.

13. Duenas Gonzalez A, Coronel J, Cetina L, González-Fierro A, Chavez-Blanco A, et al. (2014) Hydralazine valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol 10: 1433-1444.

14. Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, et al. (2015) Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics 10: 431-445.

15. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25: 469-483.

16. Banno K, Iida M, Yanokura M et al. (2015) MicroRNA in cervical cancer: oncomiRs and tumor suppressor miRs in diagnosis and treatment. Sci World J 2015: 341362.

17. www.mirbase.org/cgi-bin/mirna-summary.pl?org=hsa (accessed April 1, 2016).

18. Shah PP, Hutchinson LE, Kakar SS (2009) Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer. J Ovarian Res 2: 11.

19. Milner JA (2008) Nutrition and cancer: essential elements for a roadmap. Cancer Lett 269: 189-198.

20. Dong JY, Zhang L, He K, Qin LQ (2011) Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. Breast Cancer Res Treat 127: 23-31.

21. Dong JY, Qin LK (2011) Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective cohort studies. Breast Cancer Res Treat 125: 315-323.

22. Owen RW, Giacosa A, Hull WE, Haubner R, Spiegelhalder B, et al. (2000) The antioxidant/anticancer potential of phenolic compounds isolated from olive oil. Eur J Cancer 36: 1235-1247.

23. Di Francesco A, Falconi A, Germanio D, Micioni Di Bonaventura MV, Costa A, et al. (2015) Extravirgin olive oil up-regulates CB1 suppressor gene in human colon cancer cells and in rat colon via epigenetic mechanisms. J Nutr Biochem 26: 250-258.

24. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, et al. (2008) Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123: 552-560.

25. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, et al. (2008) Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 68: 2736-2744.

26. Pandey M, Kaur P, Shukla S, Abbas A, Fu P, et al. (2012) Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog 51: 952-962.

27. Khumar A, Dhar S, Rimando AM, Lage JM, Lewin JR, et al. (2015) Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer. Ann NY Acad Sci 1348: 1-9.

28. Chimento A, Sirianni R, Saturnino C, Caruso A, Sinicropi MS, et al. (2016) Resveratrol and its analogs as antitumoral agents for breast cancer. Mini Rev Med Chem, Mar 21 [Epub ahead of print].

29. Jeurnink S, Büchner F, Bueno-de-Mesquita H, Siersema PD, Boshuizen HC, et al. (2012) Variety in vegetable and fruit consumption and the risk of gastric and esophageal cancer in the European Prospective into cancer and nutrition. Int J Cancer131: E963-973.

30. Cooper R (2012) Green tea and teanine: health benefits. Int J Food Sci Nutr 63: 90-97.

31. Paul B, Barnes S, Demark-Wahnefried W, Morrow C, Salvador C, et al. (2015) Influences of diet and the gut microbiome on epigenetic modulations in cancer and other diseases. Clin Epigenetics 7: 112.

32. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, et al. (2009) The effect of diet on the human gut microbiome; a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1: 6ra 14.

33. Kumar H, Lund R, Laiho A, Lundelin K, Leyc RE, et al. (2014) Gut microbiota as an epigenetic regulator: pilot study based on whole-genome methylation analysis. MBio 5: e02113-e02114.

34. Candido EPM, Reeves R, Davie JR (1978) Sodium butyrate inhibites histone deacetylation in cultured cells. Get Cell 14: 105-113.

35. Hughes R, Cross AJ, Pollock JR, Bingham S (2001) Dose-dependent effect of dietary meat on endogenous colonic N-nitrosation. Carcinogenesis 22: 199-202.

36. Plotnikoff GA (2010) Interventional nutrition in cancer survivorship. A case study. Minn. Med 93: 53-58.

37. Farooqi AA, Rana A, Riaz AM, Khan A, Ali M, et al. (2012) NutriTRAILomics in prostate cancer: time to have two strings to one's bow. Mol Biol Rep 39: 4909-4914.

38. Won I, Kim YJ, Kim SJ, Kim EH, Hahm KB (2011) Nutrigenomic approach to tackle the unpleasant journey to Helicobacter pylori-associated gastric carcinogenesis. J Dig Dis 12: 157-164.